Education And Data Will Bolster Biosimilar-To-Biosimilar Switching
Sandoz Executive Hillel Cohen Discusses Misinformation And How It Can Be Overcome
In the wake of a recent paper which concluded that moving patients between two different biosimilar versions of the same brand biologic was safe and effective, Generics Bulletin speaks to Sandoz Inc executive director of scientific affairs Hillel Cohen about the growing importance of – and challenges to – biosimilar-to-biosimilar switching.
You may also be interested in...
A new paper has examined the issue of biosimilar-to-biosimilar switching, concluding that it is a safe and effective clinical practice but highlighting a lack of current health authority regulations or guidance on the subject.
Sandoz has launched a global campaign to increase uptake of biosimilars, under the banner of Act4Biosimilars. The initiative aims to increase the adoption of biosimilars by at least 30% in at least 30 countries by 2030.
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.